To date, the CDK inhibitors (CDKIs), specifically the ones that block the enzyme activity of CDK12/13 and CDK4/6, have been validated as a promising therapeutic treatment in breast cancer [40, 55, 56]. Here, CDK4 is linked to breast carcinoma.